This medication is applied across domains where additional symptomatic support is needed to address a wide variety of fungal and yeast infections.

Contending with Invasive and Central Nervous System Fungal Disease

This medicine is relevant for managing serious, deep-seated fungal infections, such as systemic candidiasis (e.g., bloodstream or organ infections) and Cryptococcal Meningitis. It helps address symptom clusters that may become intense or disruptive, contributing to easing the overall symptom load and supports the patient during difficult episodes by assisting with symptomatic relief.

Symptomatic Relief for Mucosal and Localized Thrush

It is commonly used across conditions presenting with acute episodes of mucosal and cutaneous candidiasis (e.g., thrush in the mouth, throat, or vagina). It is considered relevant in contexts that involve symptoms which may interfere with daily comfort, and offers supportive relief when symptoms create noticeable physiological strain, helping with manifestations related to inflammatory or irritative states.

Prophylactic Protection and Management of Recurrent Episodes

This medication is also relevant in conditions characterized by periods of heightened symptoms, such as the recurrence of chronic infections. It may be part of symptomatic management applied in scenarios where additional management of discomfort is required. It assists with supporting functional stability and may help patients cope more steadily with symptom fluctuations, providing symptomatic support.

---

Quick Fact: Relief for Localized Irritation

This medication is generally considered relevant for easing symptoms related to inflammatory or irritative states caused by yeast infections, which may interfere with daily comfort and create noticeable physiological strain.

Regulatory References

1. NIH MedlinePlus overview of Fluconazole

Eligibility Map: Who Can and Cannot Use Fluconazole

This section outlines the official population eligibility and non-eligibility rules for fluconazole as documented in regulatory prescribing information.

---

Populations for Whom Use is Contraindicated

The medicine must not be used by individuals with a known hypersensitivity to fluconazole, any of its components, or other azole antifungals. It is also strictly contraindicated for patients co-administering certain drugs known to prolong the QT interval, such as cisapride, astemizole, or pimozide. Use is also prohibited when fluconazole is given at high doses (400 mg/day or greater) alongside terfenadine.

---

Conditional and Restricted Use

Age-Group Eligibility: Use is established for adults, older adults, and across the pediatric age range, including neonates, though specific dosing adjustments apply to infants and neonates. Safety and efficacy for the specific treatment of vaginal candidiasis are not established in pediatric patients.

Condition-Specific Limitations: Patients with impaired renal function (Creatinine Clearance leq 50 mL/min) are eligible but require a specific dose adjustment. Caution is required when administering to patients with liver dysfunction or pre-existing cardiac arrhythmias. Pregnancy use is highly restricted, especially for high-dose or prolonged courses, and is generally reserved only for severe, life-threatening infections.

Fluconazole-Teva has a documented interaction profile primarily structured around its effects on drug metabolism. The medicine is classified as a potent inhibitor of the metabolic enzyme CYP2C9 and a moderate inhibitor of CYP2C19 and CYP3A4. This action frequently leads to a pharmacokinetic interaction where co-administered medicines that are substrates for these enzymes experience increased systemic exposure, resulting in elevated plasma concentrations.

Due to this effect, specific drug combinations are formally deemed contraindicated by regulatory authorities. These prohibitions are enforced because the increased exposure carries a high risk of serious adverse effects, notably QT prolongation and life-threatening ventricular arrhythmias. Medicines such as Cisapride, Astemizole, Pimozide, Quinidine, and Erythromycin are listed as contraindicated combinations. Co-administration with Terfenadine is also prohibited when Fluconazole doses are 400 mg or higher.

The medicine's own exposure is subject to official modification. Co-administration with the inducer Rifampicin results in a documented decrease in Fluconazole plasma levels. Conversely, concomitant use with the diuretic Hydrochlorothiazide is shown to increase Fluconazole concentration. Regulatory data explicitly confirm that the medicine's bioavailability is not affected by food or common antacids.

The primary mechanism of action occurs within fungal cells and involves the targeted inhibition of a critical enzyme, Lanosterol 14alpha -demethylase ( CYP51), a cytochrome P450 protein unique to the fungus. Fluconazole's triazole structure binds tightly and competitively to the heme iron within the enzyme's active site, thereby blocking its ability to convert lanosterol into the essential fungal lipid, ergosterol.

This enzymatic blockade disrupts the ergosterol biosynthesis pathway, resulting in two key physiological changes in the fungal cell. It causes an ergosterol deficiency, weakening the membrane's structure, and leads to the accumulation of toxic, abnormal 14alpha -methylated sterols that incorporate into the membrane. This structural compromise results in severe cellular leakage, which ultimately results in the cessation of the organism's growth and replication.

This inhibitory action can be constrained by the fungal organism's ability to actively pump the drug out of the cell. Upregulation of fungal efflux transporters ( Cdr and MDR) reduces the intracellular concentration of fluconazole, preventing attainment of inhibitory concentrations at the CYP51 target.

How Fluconazole-Teva is Used

The usage of fluconazole is standardized based on specific routes, dosing principles, and population-based adjustments. Fluconazole is administered by the oral route (tablets, capsules, or suspension) or by intravenous (IV) infusion, with the choice depending on the patient's clinical condition.

Dosing and Scheduling Principles

For most multiple-dose regimens, a loading dose of up to twice the regular daily dose is given on Day 1 to achieve plasma concentrations close to steady-state more rapidly. Dosing generally proceeds on a once daily (qDay) schedule. For infections such as Cryptococcal Meningitis, the maintenance dose may be 200 mg to 400 mg once daily but can be increased up to 800 mg per day for life-threatening cases. A single 150 mg oral dose is approved for acute vaginal candidiasis.

Treatment duration varies significantly, ranging from a single dose to maintenance therapy for up to 6 months (for recurrent candidiasis) or indefinitely (for relapse suppression in high-risk patients).

Special Administration Instructions

Instruction	General Information
Timing in relation to meals	May be taken with or without food.
Renal Impairment	For patients with creatinine clearance leq 50 mL/min, the maintenance dose should be reduced by 50% after the initial full dose.
IV Infusion Rate	Intravenous solution should be administered at a rate not exceeding 10 mL/minute.
Pediatric Dosing	Dosing is calculated based on body weight (mg/kg), and the total daily dose should not exceed 400 mg.
Missed Dose	If a dose is missed, take it as soon as possible, but do not double dose if it is near the time for the next scheduled dose.

Research Evidence / Overview of Studies for Fluconazole-Teva

The research evidence for fluconazole is based on a body of scientific work that includes Randomized Controlled Trials (RCTs), systematic reviews, and meta-analyses. These studies are essential for understanding what has been observed so far in the clinical setting. The evidence was studied for regulators to clarify the research base for specific fungal and yeast conditions.

---

Evidence for Systemic and Central Nervous System Infections

The clinical research for serious, deep-seated infections—such as when fungi are present in the bloodstream (systemic candidiasis) or the central nervous system (Cryptococcal Meningitis) — has been a primary focus. These studies explored the medicine's role, and was evaluated in trials that were often comparing different systemic antifungal agents.

Researchers studied critically ill Adults and Pediatric patients to examine how these conditions evolved over defined time intervals. The outcomes measured included mycological clearance and measurements related to overall patient mortality/survival. Some trials described patterns in these measurements when different systemic antifungal agents was observed in non-neutropenic adults. Research describes patterns related to the specific Candida species involved in the infection.

What remains uncertain is the long-term characterization of outcomes following the studied observation period for systemic candidiasis. Furthermore, existing studies provide limited insight regarding the optimal management strategies for infections caused by certain non-albicans Candida species, such as C. glabrata and C. krusei, due to their reduced susceptibility.

---

Evidence for Mucosal and Localized Fungal Disease

The evidence base for more localized and common infections, such as those occurring in the mouth, throat, or vagina, consists largely of short-course comparative and placebo-controlled RCTs. These studies explored the effect of the medicine on outcomes related to physical discomfort and acute changes in symptoms.

The research examined general Adult populations, as well as Adults and Children who may be immunocompromised. Studies reported high measurements for both symptomatic and mycological cure rates in short-term assessments of susceptible cases. Comparative trials described differences in the time before recurrence when different treatment approaches was observed in the studies. The research describes that outcomes related to acute treatment were primarily based on short-term follow-up periods.

---

Research Gaps and Uncertainties

A persistent limitation described in the research is the concern that long-term, widespread use, especially for prevention, was associated with the potential for selection pressure that may favor the emergence or colonization by inherently less susceptible fungal strains. Additionally, there is limited information for long-term outcomes or the durability of effect beyond the period of observation in most of the acute treatment trials.

Key Studies & References

1. Review of Pharmacokinetics and Pharmacodynamics of Fluconazole in Neonates and Infants

Common questions about Fluconazole-Teva (FAQ)

---

Q: How quickly does Fluconazole-Teva typically start to work?

Official product information indicates that the medicine is rapidly absorbed into the bloodstream. Following an oral dose, the highest concentration of the medicine in the blood is typically reached within one to two hours. For regimens involving multiple doses, a loading dose is sometimes used to help the drug’s concentration reach a stable level more quickly, often by the second day of use.

---

Q: Is Fluconazole-Teva a type of antibiotic?

No. Fluconazole is classified as a synthetic triazole antifungal agent, meaning it is specifically designed to target and stop the growth of fungi and yeasts. It is not an antibiotic and is not used to prevent or treat infections caused by bacteria or viruses.

---

Q: What is the difference between Fluconazole and Fluconazole-Teva?

Fluconazole is the non-proprietary name for the single active ingredient. Fluconazole-Teva is the specific product containing fluconazole that is manufactured by Teva Pharmaceuticals. The active ingredient, fluconazole, is also the same ingredient found in the brand-name product known in some regions as Diflucan.

---

Q: Can Fluconazole-Teva affect the results of a blood test?

Yes, regulatory documents note that changes in blood parameters, such as alterations in liver enzyme levels, have been reported as an uncommon side effect. Regulatory documents state that liver function monitoring may be part of the care plan for individuals receiving long-term treatment.

---

Q: Does Fluconazole-Teva interact with common pain relievers like ibuprofen?

The medicine is known to slow down the action of certain liver enzymes, including CYP2C9. Because some non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen are processed by this enzyme, taking them with fluconazole may lead to increased levels of the pain reliever in the body. This potential interaction is noted in official documentation and may necessitate careful consideration.

---

Q: What kind of infections does Fluconazole-Teva stop?

Fluconazole is indicated for treating and preventing a range of fungal and yeast infections caused by extitCandida and extitCryptococcus species. Regulatory uses include infections of the esophagus, mouth (thrush), and vagina, as well as more serious systemic infections like cryptococcal meningitis.

---

Q: Are there any specific foods or drinks to be cautious about while using this medicine?

Official data confirms that the medicine’s absorption into the body is not affected by food or common antacids. However, the medicine may slow down how quickly the body processes caffeine. Due to the potential for effects on liver function, official product information mentions the potential need for caution regarding excessive alcohol consumption.

---

Q: Is Fluconazole-Teva used for skin infections?

Yes. While commonly known for internal uses, regulatory information indicates that fluconazole is sometimes used to treat fungal infections affecting the skin and nails, in addition to deep-seated and mucosal infections.

---

Q: What should I know about taking Fluconazole-Teva if I am breastfeeding?

The medicine is known to pass into human breast milk at concentrations similar to those in the blood. Official guidance from some regulatory bodies suggests that nursing may not be recommended, particularly following repeated use or high doses, due to the lack of complete risk data for the infant.

---

Q: Is Fluconazole-Teva used to prevent future infections?

Yes, official labeling includes the use of fluconazole for prophylaxis (prevention) to decrease the risk of fungal infection. This is typically indicated for specific high-risk patient groups, such as those undergoing bone marrow transplantation.

---

Q: What is the legal age limit for prescribing Fluconazole-Teva?

The medicine is approved for use across the entire pediatric age range, including neonates, as well as for adults and older adults. Official data indicates that safety and effectiveness for treating the specific condition of vaginal candidiasis have not been established in pediatric patients.

---

Q: How does Fluconazole-Teva relate to the medicine called Diflucan?

Diflucan is the original brand name of the medicine that contains the active ingredient fluconazole. Fluconazole-Teva is the generic version of the same drug and is expected to work in the body in the same way.

---

Q: Is the effect of Fluconazole-Teva the same for men and women?

Official data on how the body handles the medicine (pharmacokinetics) does not describe any consistent differences in drug levels or how quickly the medicine is eliminated between men and women. However, certain approved uses, like treatment for vaginal candidiasis or use during pregnancy, apply only to female patients.

---

Q: What is the general classification of Fluconazole-Teva (e.g., prescription-only)?

Fluconazole-Teva is classified as a prescription medicine. This means that it is only available for use following a valid order or prescription from a licensed healthcare provider.

---

Q: How does the medicine affect blood sugar levels?

Fluconazole does not directly treat diabetes, but it can interact with certain oral diabetes medicines (sulfonylureas) by slowing down how the body processes them. This interaction is described in regulatory documents and suggests the need for careful blood glucose monitoring due to the potential risk of hypoglycemia (low blood sugar).

---

Q: Is Fluconazole-Teva ever prescribed for dental or mouth issues?

Yes. The medicine is indicated for the treatment of oropharyngeal candidiasis (often called thrush), which is a common fungal infection that affects the mouth and throat.

---

Q: What are the typical indications for a longer course of Fluconazole-Teva?

Longer courses of therapy are typically indicated for more serious, deep-seated infections, such as cryptococcal meningitis, or for maintenance treatment to prevent the relapse of recurrent candidiasis in certain high-risk patients. Treatment duration can vary widely, from a single dose to several months.

---

Q: Does the medicine come in a liquid form?

Yes. Fluconazole is supplied as oral tablets, capsules, and a powder for oral suspension. The powder is mixed with a liquid to create an oral solution for administration. It is also available as a sterile solution for intravenous infusion.

---

Q: What is the significance of the cytochrome P450 enzyme system in the context of this drug?

The cytochrome P450 (CYP450) enzyme system is important in two ways. First, fluconazole works by specifically extbfblocking a fungal CYP450 enzyme ( CYP51) to stop fungal growth. Second, fluconazole extbfinhibits certain human CYP450 enzymes in the liver, which is why it can increase the levels of other medicines taken at the same time.

---

Q: Do regulatory sources describe Fluconazole-Teva as a broad-spectrum antifungal?

While the medicine is used to treat a wide variety of fungal and yeast infections, there are limitations to its coverage. Regulatory information explicitly notes that some species, such as extitC. krusei, should generally be considered resistant, and extitC. glabrata often has reduced susceptibility, limiting its overall effective spectrum.

---

Q: Are there specific patient groups where caution is advised when using Fluconazole-Teva?

Official warnings advise caution for certain groups of patients. This includes individuals with pre-existing liver dysfunction, kidney impairment (which often requires a dose adjustment), or heart problems, including pre-existing heart rhythm disturbances or low levels of potassium.

---

Q: How long does the drug stay in your system after you stop taking it?

Official pharmacokinetic data indicates that the medicine has a relatively long elimination half-life, averaging around 30 hours in healthy adults. This means that it can take several days for a significant amount of the drug to be fully eliminated from the body after the last dose is taken.

---

Q: Is it true that Fluconazole-Teva can cause a temporary rash?

A rash is listed in regulatory documents as a common adverse reaction, but the term 'temporary' is not used in official labeling. Regulatory warnings mention the need for careful monitoring of a rash, as it may sometimes precede a rare, serious skin condition.

---

Q: What information is available regarding Fluconazole-Teva and hair loss?

Post-marketing data included in official documents mention the occurrence of alopecia, or hair loss, as a less common side effect. This has primarily been reported when the medicine is used for long-term maintenance therapy, and the effect is usually described as being reversible once the medicine is stopped.

---

Q: Are there specific symptoms that signal a rare, serious side effect?

Yes, official documents describe symptoms associated with rare, serious effects that require immediate attention. Examples include dizziness or fainting (which can signal heart rhythm problems), or a severe rash accompanied by fever, blisters, or skin peeling (signs of a severe skin reaction).

---

Q: Does official labeling mention weight-based dosing for adults?

No. Official labeling for adults generally specifies fixed daily doses in milligrams for various indications. Weight-based dosing, calculated in milligrams per kilogram, is a method of administration that is primarily defined in the pediatric patient population.

---

Q: Is it possible to take Fluconazole-Teva if I am taking birth control pills?

Fluconazole is known to affect how the body processes the hormonal components in oral contraceptives. While this is not a strict contraindication, regulatory documents indicate that the levels of certain hormones like ethinyl estradiol and levonorgestrel may be increased, which could affect the action of the birth control pill.

The official storage requirements for Fluconazole depend on the formulation to maintain stability.

Storage Requirements

Formulation	Required Temperature	Handling Constraints
Tablets/Dry Powder	Store below 30 C	Protect from light and moisture
Reconstituted Suspension	Store between 5 C and 30 C	Protect from freezing

All forms must be kept in their original, tightly closed container and stored out of the sight and reach of children.

️ Disposal Instructions

The reconstituted oral suspension must be discarded after 14 days (two weeks) of preparation. Unused or expired Fluconazole should not be flushed down the toilet or poured into a drain. It must be disposed of through a medicine take-back program or by returning it to a pharmacist, following local regulatory requirements.